Protection against Cutaneous Leishmaniasis Induced by Recombinant Antigens in Murine and Nonhuman Primate Models of the Human Disease

AUTOR(ES)

Campos-Neto, Antonio

FONTE

American Society for Microbiology

RESUMO

Leishmaniasis affects approximately 2 million people each year throughout the world. This high incidence is due in part to the lack of an efficacious vaccine. We present evidence that the recombinant leishmanial antigens LmSTI1 and TSA, which we identified and characterized previously, induce excellent protection in both murine and nonhuman primate (rhesus monkey) models of human cutaneous leishmaniasis. The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis.

Documentos Relacionados

• Creation of non-human primate neurogenetic disease models by gene targeting and nuclear transfer
• Protection of guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy.
• Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines
• Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.
• Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis